BioNTech guides for worse-than-expected 2025 revenue decline
German COVID-19 vaccine maker BioNTech on Monday said that its 2025 revenues would likely fall to between 1.7 billion euros ...
German court rules Pfizer, BioNTech violated Moderna's COVID-19 vaccine patent
A German court on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna. In ...
BioNTech initiated with a Buy at Citi
Citi analyst Geoff Meacham initiated coverage of BioNTech (BNTX) with a Buy rating and $145 price target Healthcare policy remains a key ...
Investopedia6d
BioNTech Stock Drops as Sales Outlook Disappoints
U.S.-listed shares of BioNTech fell Monday, as the COVID-19 vaccine maker’s soft sales outlook offset better-than-expected quarterly results. The German company said it expects 2025 total ...
BioNTech reports Q4 EPS EUR 1.08 vs. EUR 1.88 last year
Reports Q4 revenue EUR 1.19B vs. EUR 1.48B last year. “From the very beginning, BioNTech’s (BNTX) vision has been to translate our science into ...